SCHEMBL6605398

SCHEMBL6605398

Cc1cc(-c2ccc(C(=O)O)cc2)c(C)cn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAP4K4 O95819 7/20 0.51
▸ POLQ O75417 1/20 0.49
▸ RXRA P19793 1/20 0.47
▸ RXRB P28702 1/20 0.47
▸ ABL1 P00519 1/20 0.46
▸ GRIK1 P39086 1/20 0.44
▸ GRIA1 P42261 1/20 0.44
▸ GRIA2 P42262 1/20 0.44
▸ GRIA3 P42263 1/20 0.44
▸ GRIA4 P48058 1/20 0.44
▸ RARB P10826 1/20 0.44
▸ ADH5 P11766 2/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ AXL P30530 2/20 0.42
▸ CHEK2 O96017 1/20 0.42
▸ P4HA1 P13674 1/20 0.42
▸ MIF P14174 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16749653 0.80 RXRA (0.59) MAP4K4RXRARXRBGRIK1GRIA1
SCHEMBL12305117 0.78 CYP2A6 (0.47) POLQABL1SMN1; SMN2ALDH1A1NPC1
SCHEMBL22824136 0.78 RXRA (0.57) MAP4K4RXRARXRBGRIK1GRIA1
SCHEMBL2951077 0.77 RXRA (0.55) MAP4K4RXRARXRBGRIK1GRIA1
SCHEMBL4603074 0.77 GRIK1 (0.62) MAP4K4RXRARXRBGRIK1GRIA1
SCHEMBL30522572 0.75 UHRF1 (0.45) MAP4K4ABL1SMN1; SMN2ALDH1A1NPC1
SCHEMBL29788311 0.75 MKNK1 (0.58) MAP4K4RXRARXRBABL1SMN1; SMN2
SCHEMBL2038607 0.75 MKNK1 (0.58) MAP4K4RXRARXRBABL1SMN1; SMN2
SCHEMBL11254473 0.75 UHRF1 (0.45) MAP4K4ABL1SMN1; SMN2ALDH1A1NPC1
SCHEMBL6731024 0.75 MKNK1 (0.53) MAP4K4RXRARXRBADH5SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1190432-C Piperazing derivatives as 5-HT1B antagonists SMITHKLINE BEECHAM PLC (GB) 2005-02-23 — — CN disclosed
US-20040176388-A1 Piperazine derivatives as 5-HT1B antagonists SMITHKLINE BEECHAM P.I.C. 2004-09-09 — — US disclosed
US-6747030-B1 CIS-6-(3,5-DIMETHYLPIPERAZIN-1-YL)-5-METHOXY-1-(2'-METHYL-4'-( 5-METHYL-1,2,4-OXADIAZOL-3-YL)BIPHENYL-4-CARBONYL)INDOLINE, ITS HYDROCHLORIDE SALT, OR ANOTHER PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; ANTIDEPRESSANTS SMITHKLINE BEECHAM P.L.C. (GB) 2004-06-08 — — US disclosed
EP-1216239-B1 PIPERAZINE DERIVATIVES AS 5-HT1B ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 2004-02-11 — — EP disclosed
CN-1399635-A Piperazing derivatives as 5-HT1B antagonists SMITHKLINE BEECHAM PLC (GB) 2003-02-26 — — CN disclosed
EP-1216239-A1 PIPERAZINE DERIVATIVES AS 5-HT1B ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 2002-06-26 — — EP disclosed
WO-2001023374-A1 PIPERAZINE DERIVATIVES AS 5-HT1B ANTAGONISTS SMITHKLINE BEECHAM P.L.C. (GB) 2001-04-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176388-A1 Piperazine derivatives as 5-HT1B antagonists HTR1B, HTR2B, HTR2A MAP4K4 3553/4885POLQ 2235/4885RXRA 1763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback